Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8775272 | 1.00 | GLS (0.46) | GLSBACE1 | |
| SCHEMBL8775286 | 1.00 | GLS (0.46) | GLSBACE1 | |
| SCHEMBL18218788 | 0.83 | GLS (0.47) | GLSBACE1 | |
| SCHEMBL200462 | 0.83 | GLS (0.47) | GLSBACE1 | |
| SCHEMBL18219056 | 0.83 | GLS (0.47) | GLSBACE1 | |
| SCHEMBL18914987 | 0.83 | GLS (0.47) | GLSBACE1 | |
| SCHEMBL473047 | 0.83 | GLS (0.47) | GLSBACE1 | |
| SCHEMBL1005092 | 0.83 | GLS (0.47) | GLSBACE1 | |
| SCHEMBL23296774 | 0.81 | GLS (0.46) | GLSBACE1 | |
| SCHEMBL183678 | 0.81 | GLS (0.46) | GLSBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174969-B2 | Indoline scaffold SHP-2 inhibitors and cancer treatment method | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-11-03 | — | — | US | disclosed |
| WO-2012135669-A1 | NITROGEN RING CONTAINING COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | WEINGARTEN M DAVID (US) | 2012-10-04 | — | — | WO | disclosed |
| US-20110190315-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND CANCER TREATMENT METHOD | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010011666-A2 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND CANCER TREATMENT METHOD | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-01-28 | — | — | WO | disclosed |
| EP-0804430-A1 | SYNTHESIS OF OPTICALLY PURE 4-ALKENYL- OR 4-ALKANYL-2-HYDROXYTETRONIC ACIDS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5656662-A | TREATING OR PREVENTING ATHEROSCLEROTIC DISORDERS, INHIBITING INFLAMMATORY CYTOKINES | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1997-08-12 | — | — | US | disclosed |
| US-5504107-A | ANTICOAGULANTS, PREVENTING ATHEROSCLEROSIS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1996-04-02 | — | — | US | disclosed |
| WO-1995032194-A1 | SYNTHESIS OF OPTICALLY PURE 4-ALKENYL- OR 4-ALKANYL-2-HYDROXYTETRONIC ACIDS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1995-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190315-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND CANCER TREATMENT METHOD | PTPN7, PTPN3, PTPN5 | GLS 4067/4885BACE1 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.